1. Home
  2. KNSA vs GTX Comparison

KNSA vs GTX Comparison

Compare KNSA & GTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KNSA
  • GTX
  • Stock Information
  • Founded
  • KNSA 2015
  • GTX 2018
  • Country
  • KNSA United Kingdom
  • GTX Switzerland
  • Employees
  • KNSA N/A
  • GTX N/A
  • Industry
  • KNSA Biotechnology: Pharmaceutical Preparations
  • GTX Auto Parts:O.E.M.
  • Sector
  • KNSA Health Care
  • GTX Consumer Discretionary
  • Exchange
  • KNSA Nasdaq
  • GTX Nasdaq
  • Market Cap
  • KNSA 2.1B
  • GTX 2.0B
  • IPO Year
  • KNSA 2018
  • GTX N/A
  • Fundamental
  • Price
  • KNSA $27.53
  • GTX $10.54
  • Analyst Decision
  • KNSA Strong Buy
  • GTX Strong Buy
  • Analyst Count
  • KNSA 5
  • GTX 1
  • Target Price
  • KNSA $38.80
  • GTX $14.00
  • AVG Volume (30 Days)
  • KNSA 1.1M
  • GTX 3.0M
  • Earning Date
  • KNSA 07-22-2025
  • GTX 07-24-2025
  • Dividend Yield
  • KNSA N/A
  • GTX 2.28%
  • EPS Growth
  • KNSA N/A
  • GTX N/A
  • EPS
  • KNSA N/A
  • GTX 1.28
  • Revenue
  • KNSA $481,166,000.00
  • GTX $3,438,000,000.00
  • Revenue This Year
  • KNSA $37.21
  • GTX $1.06
  • Revenue Next Year
  • KNSA $5.32
  • GTX $6.41
  • P/E Ratio
  • KNSA N/A
  • GTX $8.18
  • Revenue Growth
  • KNSA 59.45
  • GTX N/A
  • 52 Week Low
  • KNSA $17.38
  • GTX $7.02
  • 52 Week High
  • KNSA $30.69
  • GTX $12.09
  • Technical
  • Relative Strength Index (RSI)
  • KNSA 54.29
  • GTX 53.34
  • Support Level
  • KNSA $27.62
  • GTX $9.57
  • Resistance Level
  • KNSA $29.23
  • GTX $10.56
  • Average True Range (ATR)
  • KNSA 1.03
  • GTX 0.29
  • MACD
  • KNSA -0.21
  • GTX 0.01
  • Stochastic Oscillator
  • KNSA 46.99
  • GTX 93.47

About KNSA Kiniksa Pharmaceuticals Ltd.

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.

About GTX Garrett Motion Inc.

Garrett Motion Inc designs, manufactures and sells engineered turbocharger and electric-boosting technologies for light and commercial vehicle original equipment manufacturers (OEMs). The company is a technology leader with expertise in delivering products across gasoline, diesel, natural gas and electrified powertrains. The company also sells its technologies in the aftermarket through its distribution network. The company derives maximum of its revenue from Gas and geographically from Europe.

Share on Social Networks: